Clinical trial

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

NCT01680991

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-09-01

PhasePHASE1

Study timeline

Study start (unknown)2012-09-01Date precision: month

Registry last updated2016-04-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphomaunresolved

Interventions

ObinutuzumabDRUG · verified · RxNorm: obinutuzumab

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

BeijingChina2 ShanghaiChina1 GuangzhouChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01680991 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.